期刊
GLIA
卷 68, 期 4, 页码 705-720出版社
WILEY
DOI: 10.1002/glia.23733
关键词
drug screen; iPSC; myelin diseases; oligodendrocytes; stem cells; transplantation
资金
- AFM-TELETHON [2016-20270]
- Association Europeenne contre les Leucodystrophies [2017-018C4A]
- Deutsche Forschungsgemeinschaft [CRC-TR-128B07]
- ECTRIMS postdoctoral fellowship
- National Multiple Sclerosis Society [RG-1801-30020]
- Progressive MS Alliance [PA-1604-08492]
Oligodendroglial pathology is central to de- and dysmyelinating, but also contributes to neurodegenerative and psychiatric diseases as well as brain injury. The understanding of oligodendroglial biology in health and disease has been significantly increased during recent years by experimental in vitro and in vivo preclinical studies as well as histological analyses of human tissue samples. However, for many of these diseases the underlying pathology is still not fully understood and treatment options are frequently lacking. This is at least partly caused by the limited access to human oligodendrocytes from patients to perform functional studies and drug screens. The induced pluripotent stem cell technology (iPSC) represents a possibility to circumvent this obstacle and paves new ways to study human disease and to develop new treatment options for so far incurable central nervous system (CNS) diseases. In this review, we summarize the differences between human and rodent oligodendrocytes, provide an overview of the different techniques to generate oligodendrocytes from human progenitor or stem cells and describe the results from studies using iPSC derived oligodendroglial lineage cells. Furthermore, we discuss future perspectives and challenges of the iPSC technology with respect to disease modeling, drug screen, and cell transplantation approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据